Clinical guideline for male lower urinary tract symptoms
: This article is a shortened version of the clinical guideline for lower urinary tract symptoms (LUTS), which has been developed in Japan for symptomatic men aged 50 years and over irrespective of presumed diagnoses. The guideline was formed on the PubMed database between 1995 and 2007 and other r...
Gespeichert in:
Veröffentlicht in: | International journal of urology 2009-10, Vol.16 (10), p.775-790 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 790 |
---|---|
container_issue | 10 |
container_start_page | 775 |
container_title | International journal of urology |
container_volume | 16 |
creator | Homma, Yukio Araki, Isao Igawa, Yasuhiko Ozono, Seiichiro Gotoh, Momokazu Yamanishi, Tomonori Yokoyama, Osamu Yoshida, Masaki |
description | : This article is a shortened version of the clinical guideline for lower urinary tract symptoms (LUTS), which has been developed in Japan for symptomatic men aged 50 years and over irrespective of presumed diagnoses. The guideline was formed on the PubMed database between 1995 and 2007 and other relevant sources. The causes of male LUTS are diverse and attributable to diseases/dysfunctions of the lower urinary tract, prostate, nervous system, and other organ systems, with benign prostatic hyperplasia, bladder dysfunction, polyuria, and their combination being most common. The mandatory assessment should comprise medical history, physical examination, urinalysis, and measurement of serum prostate‐specific antigen. Symptom and quality of life questionnaires, bladder diary, residual urine measurement, urine cytology, urine culture, measurement of serum creatinine, and urinary tract ultrasonography would be optional tests. The Core Lower Urinary Tract Symptom Score Questionnaire may be useful in quickly capturing important symptoms. Severe symptoms, pain symptoms, and other clinical problems would indicate urological referral. One should be careful not to overlook underlying diseases such as infection or malignancy. The treatment should be initiated with conservative therapy and/or medicine such as α1‐blockers. Treatment with anticholinergic agents should be reserved only for urologists, considering the risk of urinary retention. The present guideline should help urologists and especially non‐urologists treat men with LUTS. |
doi_str_mv | 10.1111/j.1442-2042.2009.02369.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734077659</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734077659</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5759-94ef79be677d548b5d403e55e6df360a6e875ec1af9488ee15c0e9bfbd1a84c63</originalsourceid><addsrcrecordid>eNqNkD1PwzAQhi0EoqXwF1A2pgQ78efAgCoorUphaMVoOckFpSRNsRO1_fckpCorXuyT3-fu9CDkERyQ9tyvA0Jp6IeYhkGIsQpwGHEV7M_Q8PRxjoZYEeVLIsIBunJujTGJQiIv0YAoSQijYojkuMg3eWIK77PJU2gL8LLKeqUpwCuqHVivsfnG2INXW5PUnjuU27oq3TW6yEzh4OZ4j9Dq-Wk5fvHnb5Pp-HHuJ0ww5SsKmVAxcCFSRmXMUoojYAx4mkUcGw5SMEiIyRSVEoCwBIOKszglRtKERyN01_fd2uq7AVfrMncJFIXZQNU4LSKKheBMtUnZJxNbOWch01ubl-3mmmDdadNr3dnRnR3dadO_2vS-RW-PQ5q4hPQPPHpqAw99YJcXcPh3Yz2drbpXy_s9n7sa9ife2C_NRSSY_lhMNJu9qnDxzvUy-gEGKYqO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734077659</pqid></control><display><type>article</type><title>Clinical guideline for male lower urinary tract symptoms</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Homma, Yukio ; Araki, Isao ; Igawa, Yasuhiko ; Ozono, Seiichiro ; Gotoh, Momokazu ; Yamanishi, Tomonori ; Yokoyama, Osamu ; Yoshida, Masaki</creator><creatorcontrib>Homma, Yukio ; Araki, Isao ; Igawa, Yasuhiko ; Ozono, Seiichiro ; Gotoh, Momokazu ; Yamanishi, Tomonori ; Yokoyama, Osamu ; Yoshida, Masaki ; Japanese Society of Neurogenic Bladder</creatorcontrib><description>: This article is a shortened version of the clinical guideline for lower urinary tract symptoms (LUTS), which has been developed in Japan for symptomatic men aged 50 years and over irrespective of presumed diagnoses. The guideline was formed on the PubMed database between 1995 and 2007 and other relevant sources. The causes of male LUTS are diverse and attributable to diseases/dysfunctions of the lower urinary tract, prostate, nervous system, and other organ systems, with benign prostatic hyperplasia, bladder dysfunction, polyuria, and their combination being most common. The mandatory assessment should comprise medical history, physical examination, urinalysis, and measurement of serum prostate‐specific antigen. Symptom and quality of life questionnaires, bladder diary, residual urine measurement, urine cytology, urine culture, measurement of serum creatinine, and urinary tract ultrasonography would be optional tests. The Core Lower Urinary Tract Symptom Score Questionnaire may be useful in quickly capturing important symptoms. Severe symptoms, pain symptoms, and other clinical problems would indicate urological referral. One should be careful not to overlook underlying diseases such as infection or malignancy. The treatment should be initiated with conservative therapy and/or medicine such as α1‐blockers. Treatment with anticholinergic agents should be reserved only for urologists, considering the risk of urinary retention. The present guideline should help urologists and especially non‐urologists treat men with LUTS.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/j.1442-2042.2009.02369.x</identifier><identifier>PMID: 19811547</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>Algorithms ; benign prostatic hyperplasia ; guideline ; Humans ; lower urinary tract symptoms ; Male ; men ; Prostatism - diagnosis ; Prostatism - etiology ; Prostatism - therapy ; α1-blockers</subject><ispartof>International journal of urology, 2009-10, Vol.16 (10), p.775-790</ispartof><rights>2009 The Japanese Urological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5759-94ef79be677d548b5d403e55e6df360a6e875ec1af9488ee15c0e9bfbd1a84c63</citedby><cites>FETCH-LOGICAL-c5759-94ef79be677d548b5d403e55e6df360a6e875ec1af9488ee15c0e9bfbd1a84c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1442-2042.2009.02369.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1442-2042.2009.02369.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19811547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Homma, Yukio</creatorcontrib><creatorcontrib>Araki, Isao</creatorcontrib><creatorcontrib>Igawa, Yasuhiko</creatorcontrib><creatorcontrib>Ozono, Seiichiro</creatorcontrib><creatorcontrib>Gotoh, Momokazu</creatorcontrib><creatorcontrib>Yamanishi, Tomonori</creatorcontrib><creatorcontrib>Yokoyama, Osamu</creatorcontrib><creatorcontrib>Yoshida, Masaki</creatorcontrib><creatorcontrib>Japanese Society of Neurogenic Bladder</creatorcontrib><title>Clinical guideline for male lower urinary tract symptoms</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>: This article is a shortened version of the clinical guideline for lower urinary tract symptoms (LUTS), which has been developed in Japan for symptomatic men aged 50 years and over irrespective of presumed diagnoses. The guideline was formed on the PubMed database between 1995 and 2007 and other relevant sources. The causes of male LUTS are diverse and attributable to diseases/dysfunctions of the lower urinary tract, prostate, nervous system, and other organ systems, with benign prostatic hyperplasia, bladder dysfunction, polyuria, and their combination being most common. The mandatory assessment should comprise medical history, physical examination, urinalysis, and measurement of serum prostate‐specific antigen. Symptom and quality of life questionnaires, bladder diary, residual urine measurement, urine cytology, urine culture, measurement of serum creatinine, and urinary tract ultrasonography would be optional tests. The Core Lower Urinary Tract Symptom Score Questionnaire may be useful in quickly capturing important symptoms. Severe symptoms, pain symptoms, and other clinical problems would indicate urological referral. One should be careful not to overlook underlying diseases such as infection or malignancy. The treatment should be initiated with conservative therapy and/or medicine such as α1‐blockers. Treatment with anticholinergic agents should be reserved only for urologists, considering the risk of urinary retention. The present guideline should help urologists and especially non‐urologists treat men with LUTS.</description><subject>Algorithms</subject><subject>benign prostatic hyperplasia</subject><subject>guideline</subject><subject>Humans</subject><subject>lower urinary tract symptoms</subject><subject>Male</subject><subject>men</subject><subject>Prostatism - diagnosis</subject><subject>Prostatism - etiology</subject><subject>Prostatism - therapy</subject><subject>α1-blockers</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkD1PwzAQhi0EoqXwF1A2pgQ78efAgCoorUphaMVoOckFpSRNsRO1_fckpCorXuyT3-fu9CDkERyQ9tyvA0Jp6IeYhkGIsQpwGHEV7M_Q8PRxjoZYEeVLIsIBunJujTGJQiIv0YAoSQijYojkuMg3eWIK77PJU2gL8LLKeqUpwCuqHVivsfnG2INXW5PUnjuU27oq3TW6yEzh4OZ4j9Dq-Wk5fvHnb5Pp-HHuJ0ww5SsKmVAxcCFSRmXMUoojYAx4mkUcGw5SMEiIyRSVEoCwBIOKszglRtKERyN01_fd2uq7AVfrMncJFIXZQNU4LSKKheBMtUnZJxNbOWch01ubl-3mmmDdadNr3dnRnR3dadO_2vS-RW-PQ5q4hPQPPHpqAw99YJcXcPh3Yz2drbpXy_s9n7sa9ife2C_NRSSY_lhMNJu9qnDxzvUy-gEGKYqO</recordid><startdate>200910</startdate><enddate>200910</enddate><creator>Homma, Yukio</creator><creator>Araki, Isao</creator><creator>Igawa, Yasuhiko</creator><creator>Ozono, Seiichiro</creator><creator>Gotoh, Momokazu</creator><creator>Yamanishi, Tomonori</creator><creator>Yokoyama, Osamu</creator><creator>Yoshida, Masaki</creator><general>Blackwell Publishing Asia</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200910</creationdate><title>Clinical guideline for male lower urinary tract symptoms</title><author>Homma, Yukio ; Araki, Isao ; Igawa, Yasuhiko ; Ozono, Seiichiro ; Gotoh, Momokazu ; Yamanishi, Tomonori ; Yokoyama, Osamu ; Yoshida, Masaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5759-94ef79be677d548b5d403e55e6df360a6e875ec1af9488ee15c0e9bfbd1a84c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Algorithms</topic><topic>benign prostatic hyperplasia</topic><topic>guideline</topic><topic>Humans</topic><topic>lower urinary tract symptoms</topic><topic>Male</topic><topic>men</topic><topic>Prostatism - diagnosis</topic><topic>Prostatism - etiology</topic><topic>Prostatism - therapy</topic><topic>α1-blockers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Homma, Yukio</creatorcontrib><creatorcontrib>Araki, Isao</creatorcontrib><creatorcontrib>Igawa, Yasuhiko</creatorcontrib><creatorcontrib>Ozono, Seiichiro</creatorcontrib><creatorcontrib>Gotoh, Momokazu</creatorcontrib><creatorcontrib>Yamanishi, Tomonori</creatorcontrib><creatorcontrib>Yokoyama, Osamu</creatorcontrib><creatorcontrib>Yoshida, Masaki</creatorcontrib><creatorcontrib>Japanese Society of Neurogenic Bladder</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Homma, Yukio</au><au>Araki, Isao</au><au>Igawa, Yasuhiko</au><au>Ozono, Seiichiro</au><au>Gotoh, Momokazu</au><au>Yamanishi, Tomonori</au><au>Yokoyama, Osamu</au><au>Yoshida, Masaki</au><aucorp>Japanese Society of Neurogenic Bladder</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical guideline for male lower urinary tract symptoms</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2009-10</date><risdate>2009</risdate><volume>16</volume><issue>10</issue><spage>775</spage><epage>790</epage><pages>775-790</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>: This article is a shortened version of the clinical guideline for lower urinary tract symptoms (LUTS), which has been developed in Japan for symptomatic men aged 50 years and over irrespective of presumed diagnoses. The guideline was formed on the PubMed database between 1995 and 2007 and other relevant sources. The causes of male LUTS are diverse and attributable to diseases/dysfunctions of the lower urinary tract, prostate, nervous system, and other organ systems, with benign prostatic hyperplasia, bladder dysfunction, polyuria, and their combination being most common. The mandatory assessment should comprise medical history, physical examination, urinalysis, and measurement of serum prostate‐specific antigen. Symptom and quality of life questionnaires, bladder diary, residual urine measurement, urine cytology, urine culture, measurement of serum creatinine, and urinary tract ultrasonography would be optional tests. The Core Lower Urinary Tract Symptom Score Questionnaire may be useful in quickly capturing important symptoms. Severe symptoms, pain symptoms, and other clinical problems would indicate urological referral. One should be careful not to overlook underlying diseases such as infection or malignancy. The treatment should be initiated with conservative therapy and/or medicine such as α1‐blockers. Treatment with anticholinergic agents should be reserved only for urologists, considering the risk of urinary retention. The present guideline should help urologists and especially non‐urologists treat men with LUTS.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>19811547</pmid><doi>10.1111/j.1442-2042.2009.02369.x</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0919-8172 |
ispartof | International journal of urology, 2009-10, Vol.16 (10), p.775-790 |
issn | 0919-8172 1442-2042 |
language | eng |
recordid | cdi_proquest_miscellaneous_734077659 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Algorithms benign prostatic hyperplasia guideline Humans lower urinary tract symptoms Male men Prostatism - diagnosis Prostatism - etiology Prostatism - therapy α1-blockers |
title | Clinical guideline for male lower urinary tract symptoms |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T18%3A04%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20guideline%20for%20male%20lower%20urinary%20tract%20symptoms&rft.jtitle=International%20journal%20of%20urology&rft.au=Homma,%20Yukio&rft.aucorp=Japanese%20Society%20of%20Neurogenic%20Bladder&rft.date=2009-10&rft.volume=16&rft.issue=10&rft.spage=775&rft.epage=790&rft.pages=775-790&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/j.1442-2042.2009.02369.x&rft_dat=%3Cproquest_cross%3E734077659%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734077659&rft_id=info:pmid/19811547&rfr_iscdi=true |